問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

3103Cases

2016-05-01 - 2018-09-30

Phase III

A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro esophageal junction

  • Condition/Disease

    Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

  • Test Drug

    avelumab

Participate Sites
10Sites

Terminated9Sites

陳仁熙
Linkou Chang Gung Medical Foundation

白禮源
China Medical University Hospital-Taipei

未分科

2017-03-14 - 2025-05-13

Phase II

An Open-Label, Multicenter, Global Phase 2 Basket Study of for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Entrectinib Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

  • Condition/Disease

    Locally Advanced or Metastatic Solid Tumors that Entrectinib Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

  • Test Drug

    Entrectinib

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

羅永鴻
Taipei Veterans General Hospital

2015-10-01 - 2022-06-22

Phase III

A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum-based doublet as a first-line treatment of recurrent or Stage IV PD-L1+ non–small-cell lung cancer

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    Avelumab

Participate Sites
7Sites

Terminated7Sites

2016-01-01 - 2017-12-08

Phase III

A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis

  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    ENTYVIO; KYNTELES

Participate Sites
5Sites

Terminated4Sites

吳登強
Kaohsiung Municipal Gangshan Hospital

未分科

2015-10-30 - 2019-04-27

Phase II

A Phase 2, Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients with Paroxysmal Nocturnal Hemoglobinuria

  • Condition/Disease

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • Test Drug

    ALXN1210

Participate Sites
2Sites

Terminated2Sites

2015-09-01 - 2016-07-31

Phase III

A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2)

  • Condition/Disease

    Chronic Liver Disease (CLD)

  • Test Drug

    S-888711

Participate Sites
3Sites

Terminated2Sites

2015-10-01 - 2017-02-15

Phase III

A Phase III open-label, multicenter trial of avelumab (MSB0010718C) as a third-line treatment of unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma

  • Condition/Disease

    unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma

  • Test Drug

    Avelumab

Participate Sites
7Sites

Terminated5Sites

Study ended1Sites

2015-06-01 - 2018-12-31

Phase III

A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet

  • Condition/Disease

    NSCLC

  • Test Drug

    avelumab

Participate Sites
6Sites

Terminated6Sites

楊政達
Linkou Chang Gung Medical Foundation

2015-08-01 - 2017-12-31

Phase I

Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study To evaluate The Safety, Tolerability, And Immunogenicity Of INO-1800 Alone Or in Combination With INO-9112 Delivered IM Followed By Electroporation In Select Nucleos(t)ide Analogue-Treated, HBeAG-Positive, Chronic Hepatitis B Patients

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    INO-1800 and INO-9112

Participate Sites
6Sites

Terminated5Sites

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

莊萬龍
Kaohsiung Municipal Gangshan Hospital

未分科

2015-12-01 - 2021-12-31

Phase III

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer′s Disease

  • Condition/Disease

    Alzheimer′s disease

  • Test Drug

    Aducanumab

Participate Sites
8Sites

Terminated7Sites

劉景寬
Kaohsiung Municipal Gangshan Hospital

未分科

劉景寬
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

1 255 256 257 258 259 311
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB